2025 Q4 -tulosraportti
57 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Viimeisin osinko
4,94%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·1 t sitten100% tariff from Trump on pharmaceuticals. Have a nice Easter Dane 🐣🫶
·1 t sitten · MuokattuNew comparative data gives the Wegovy pill the upper hand While the market yesterday focused on Eli Lilly's FDA approval of their first obesity pill, Foundayo (orforglipron), Novo Nordisk today presented strong data positioning their oral 25 mg semaglutide (Wegovy in pill form) as market leader in efficacy. Here are the key points from the fresh analysis presented at the Obesity Medicine Association (OMA) in San Diego this week: 1. Efficacy gap: +3.2 % in favor of Novo Through an indirect treatment comparison (ITC) based on the ORION program, the data shows that: * Novo Nordisk's 25 mg oral semaglutide achieved an average weight loss that was 3.2 % higher than Lilly's 36 mg orforglipron. * Although both medicines are highly effective, this gap is statistically significant and could be decisive for doctors choosing treatment for their patients. 2. Tolerance and adherence One of the biggest challenges with GLP-1 medications in tablet form is side effects like nausea. Novo's data indicates that the likelihood of patients discontinuing treatment due to side effects was lower for oral semaglutide than for Lilly's alternative. This is critical for long-term treatment of chronic obesity. 3. Patients prefer Novo's profile Novo also presented figures from an extensive patient survey (November 2025): * 84 % of respondents preferred treatment characteristics consistent with Novo's pill. * This includes factors such as dosing flexibility and the established safety profile of the semaglutide molecule. Strategic assessment Lilly's pill (Foundayo) has an advantage in that it does not require fasting before intake, but Novo's response shows that they are betting everything on maximum efficacy. In a market increasingly characterized by competition, the "gold standard" for weight loss will often carry the most weight with specialists. The fact that Novo published this just hours after Lilly's approval shows an aggressive and confident market strategy References: • Novo Nordisk Newsroom (Official announcements): Novo Nordisk News & IR Materials – Here you can find the full announcement about the ORION data published April 2, 2026. • Conference information (OMA 2026): Obesity Medicine Association - Annual Meeting – Complete datasets from the ORION study will be available here during the congress April 8–12.
·44 min sittenWhat it means in practice: • 100 % tariffs are not for everyone • It is a leverage against companies that: • do not cooperate • do not invest in the USA 👉 Novo is already: • “on the inside” • in dialogue • willing to invest ⸻ 📊 Market reaction (very important) The market often only reads the headline: 👉 “100 % tariffs on medicines” = panic 📉 But the reality: 👉 Novo is among those who will probably be exempt- ·1 t sittenNew comparative data gives the Wegovy pill the upper hand While the market yesterday focused on Eli Lilly's FDA approval of their first obesity pill, Foundayo (orforglipron), Novo Nordisk today presented strong data positioning their oral 25 mg semaglutide (Wegovy in pill form) as market-leading in efficacy. Here are the key points from the fresh analysis being presented at the Obesity Medicine Association (OMA) in San Diego this week: 1. Efficacy gap: +3.2 % in Novo's favor Through an indirect treatment comparison (ITC) study based on the ORION program, the data shows that: * Novo Nordisk's 25 mg oral semaglutide achieved an average weight loss that was 3.2 % higher than Lilly's 36 mg orforglipron. * Although both medications are highly effective, this gap is statistically significant and could be decisive for doctors choosing treatment for their patients. 2. Tolerability and adherence One of the biggest challenges with GLP-1 medications in tablet form is side effects such as nausea. Novo's data indicates that the likelihood of patients discontinuing treatment due to side effects was lower for oral semaglutide than for Lilly's alternative. This is critical for long-term treatment of chronic obesity. 3. Patients prefer Novo's profile Novo also presented figures from a comprehensive patient survey (November 2025): * 84 % of respondents preferred treatment characteristics consistent with Novo's pill. * This includes factors such as dosing flexibility and the established safety profile of the semaglutide molecule. Strategic assessment Lilly's pill (Foundayo) has an advantage in that it does not require fasting before intake, but Novo's response shows that they are betting everything on maximum efficacy. In a market increasingly characterized by competition, the "gold standard" for weight loss will often carry the most weight with specialists. That Novo publishes this just hours after Lilly's approval shows an aggressive and confident market strategy References: • Novo Nordisk Newsroom (Official announcements): Novo Nordisk News & IR Materials – Here you will find the full announcement about the ORION data published April 2, 2026. • Details on competitor's approval (Eli Lilly - Foundayo): PR Newswire: FDA approves Lilly’s Foundayo™ (orforglipron) • Medical coverage of the case: TIME: FDA Approves Eli Lilly’s Obesity Pill, Foundayo • Conference information (OMA 2026): Obesity Medicine Association - Annual Meeting – Complete posters and datasets from the ORION study will be available here during the congress April 8–12.
·3 t sittenTrump with tough message: 100 percent tariff Donald Trump is putting massive pressure on the pharmaceutical industry with a new, tough plan. The USA will introduce a 100 percent tariff on patented medicine that is not produced in the USA or is not part of price agreements with the authorities, Reuters writes. The companies get 120 days to comply, otherwise the hammer will fall. They can, however, get off cheaper by moving production to the USA or entering into agreements on lower prices. The measure is intended to push down medicine prices in the USA, where patients today pay significantly more than in other rich countries. The Danish pharmaceutical giant Novo Nordisk has already entered into an agreement with the American administration on lower prices for diabetes and obesity medicine. This happened in november.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
57 päivää sitten
‧1 t 12 min
7,95 DKK/osake
Viimeisin osinko
4,94%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sitten100% tariff from Trump on pharmaceuticals. Have a nice Easter Dane 🐣🫶
- ·1 t sitten · MuokattuNew comparative data gives the Wegovy pill the upper hand While the market yesterday focused on Eli Lilly's FDA approval of their first obesity pill, Foundayo (orforglipron), Novo Nordisk today presented strong data positioning their oral 25 mg semaglutide (Wegovy in pill form) as market leader in efficacy. Here are the key points from the fresh analysis presented at the Obesity Medicine Association (OMA) in San Diego this week: 1. Efficacy gap: +3.2 % in favor of Novo Through an indirect treatment comparison (ITC) based on the ORION program, the data shows that: * Novo Nordisk's 25 mg oral semaglutide achieved an average weight loss that was 3.2 % higher than Lilly's 36 mg orforglipron. * Although both medicines are highly effective, this gap is statistically significant and could be decisive for doctors choosing treatment for their patients. 2. Tolerance and adherence One of the biggest challenges with GLP-1 medications in tablet form is side effects like nausea. Novo's data indicates that the likelihood of patients discontinuing treatment due to side effects was lower for oral semaglutide than for Lilly's alternative. This is critical for long-term treatment of chronic obesity. 3. Patients prefer Novo's profile Novo also presented figures from an extensive patient survey (November 2025): * 84 % of respondents preferred treatment characteristics consistent with Novo's pill. * This includes factors such as dosing flexibility and the established safety profile of the semaglutide molecule. Strategic assessment Lilly's pill (Foundayo) has an advantage in that it does not require fasting before intake, but Novo's response shows that they are betting everything on maximum efficacy. In a market increasingly characterized by competition, the "gold standard" for weight loss will often carry the most weight with specialists. The fact that Novo published this just hours after Lilly's approval shows an aggressive and confident market strategy References: • Novo Nordisk Newsroom (Official announcements): Novo Nordisk News & IR Materials – Here you can find the full announcement about the ORION data published April 2, 2026. • Conference information (OMA 2026): Obesity Medicine Association - Annual Meeting – Complete datasets from the ORION study will be available here during the congress April 8–12.·44 min sittenWhat it means in practice: • 100 % tariffs are not for everyone • It is a leverage against companies that: • do not cooperate • do not invest in the USA 👉 Novo is already: • “on the inside” • in dialogue • willing to invest ⸻ 📊 Market reaction (very important) The market often only reads the headline: 👉 “100 % tariffs on medicines” = panic 📉 But the reality: 👉 Novo is among those who will probably be exempt
- ·1 t sittenNew comparative data gives the Wegovy pill the upper hand While the market yesterday focused on Eli Lilly's FDA approval of their first obesity pill, Foundayo (orforglipron), Novo Nordisk today presented strong data positioning their oral 25 mg semaglutide (Wegovy in pill form) as market-leading in efficacy. Here are the key points from the fresh analysis being presented at the Obesity Medicine Association (OMA) in San Diego this week: 1. Efficacy gap: +3.2 % in Novo's favor Through an indirect treatment comparison (ITC) study based on the ORION program, the data shows that: * Novo Nordisk's 25 mg oral semaglutide achieved an average weight loss that was 3.2 % higher than Lilly's 36 mg orforglipron. * Although both medications are highly effective, this gap is statistically significant and could be decisive for doctors choosing treatment for their patients. 2. Tolerability and adherence One of the biggest challenges with GLP-1 medications in tablet form is side effects such as nausea. Novo's data indicates that the likelihood of patients discontinuing treatment due to side effects was lower for oral semaglutide than for Lilly's alternative. This is critical for long-term treatment of chronic obesity. 3. Patients prefer Novo's profile Novo also presented figures from a comprehensive patient survey (November 2025): * 84 % of respondents preferred treatment characteristics consistent with Novo's pill. * This includes factors such as dosing flexibility and the established safety profile of the semaglutide molecule. Strategic assessment Lilly's pill (Foundayo) has an advantage in that it does not require fasting before intake, but Novo's response shows that they are betting everything on maximum efficacy. In a market increasingly characterized by competition, the "gold standard" for weight loss will often carry the most weight with specialists. That Novo publishes this just hours after Lilly's approval shows an aggressive and confident market strategy References: • Novo Nordisk Newsroom (Official announcements): Novo Nordisk News & IR Materials – Here you will find the full announcement about the ORION data published April 2, 2026. • Details on competitor's approval (Eli Lilly - Foundayo): PR Newswire: FDA approves Lilly’s Foundayo™ (orforglipron) • Medical coverage of the case: TIME: FDA Approves Eli Lilly’s Obesity Pill, Foundayo • Conference information (OMA 2026): Obesity Medicine Association - Annual Meeting – Complete posters and datasets from the ORION study will be available here during the congress April 8–12.
- ·3 t sittenTrump with tough message: 100 percent tariff Donald Trump is putting massive pressure on the pharmaceutical industry with a new, tough plan. The USA will introduce a 100 percent tariff on patented medicine that is not produced in the USA or is not part of price agreements with the authorities, Reuters writes. The companies get 120 days to comply, otherwise the hammer will fall. They can, however, get off cheaper by moving production to the USA or entering into agreements on lower prices. The measure is intended to push down medicine prices in the USA, where patients today pay significantly more than in other rich countries. The Danish pharmaceutical giant Novo Nordisk has already entered into an agreement with the American administration on lower prices for diabetes and obesity medicine. This happened in november.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
2025 Q4 -tulosraportti
57 päivää sitten
‧1 t 12 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 6.5. |
| Menneet tapahtumat | ||
|---|---|---|
Vuosittainen yhtiökokous 2026 26.3. | ||
2025 Q4 -tulosraportti 4.2. | ||
Ylimääräinen yhtiökokous 2025 14.11.2025 | ||
2025 Q3 -tulosraportti 5.11.2025 | ||
2025 Q2 -tulosraportti 6.8.2025 |
7,95 DKK/osake
Viimeisin osinko
4,94%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·1 t sitten100% tariff from Trump on pharmaceuticals. Have a nice Easter Dane 🐣🫶
- ·1 t sitten · MuokattuNew comparative data gives the Wegovy pill the upper hand While the market yesterday focused on Eli Lilly's FDA approval of their first obesity pill, Foundayo (orforglipron), Novo Nordisk today presented strong data positioning their oral 25 mg semaglutide (Wegovy in pill form) as market leader in efficacy. Here are the key points from the fresh analysis presented at the Obesity Medicine Association (OMA) in San Diego this week: 1. Efficacy gap: +3.2 % in favor of Novo Through an indirect treatment comparison (ITC) based on the ORION program, the data shows that: * Novo Nordisk's 25 mg oral semaglutide achieved an average weight loss that was 3.2 % higher than Lilly's 36 mg orforglipron. * Although both medicines are highly effective, this gap is statistically significant and could be decisive for doctors choosing treatment for their patients. 2. Tolerance and adherence One of the biggest challenges with GLP-1 medications in tablet form is side effects like nausea. Novo's data indicates that the likelihood of patients discontinuing treatment due to side effects was lower for oral semaglutide than for Lilly's alternative. This is critical for long-term treatment of chronic obesity. 3. Patients prefer Novo's profile Novo also presented figures from an extensive patient survey (November 2025): * 84 % of respondents preferred treatment characteristics consistent with Novo's pill. * This includes factors such as dosing flexibility and the established safety profile of the semaglutide molecule. Strategic assessment Lilly's pill (Foundayo) has an advantage in that it does not require fasting before intake, but Novo's response shows that they are betting everything on maximum efficacy. In a market increasingly characterized by competition, the "gold standard" for weight loss will often carry the most weight with specialists. The fact that Novo published this just hours after Lilly's approval shows an aggressive and confident market strategy References: • Novo Nordisk Newsroom (Official announcements): Novo Nordisk News & IR Materials – Here you can find the full announcement about the ORION data published April 2, 2026. • Conference information (OMA 2026): Obesity Medicine Association - Annual Meeting – Complete datasets from the ORION study will be available here during the congress April 8–12.·44 min sittenWhat it means in practice: • 100 % tariffs are not for everyone • It is a leverage against companies that: • do not cooperate • do not invest in the USA 👉 Novo is already: • “on the inside” • in dialogue • willing to invest ⸻ 📊 Market reaction (very important) The market often only reads the headline: 👉 “100 % tariffs on medicines” = panic 📉 But the reality: 👉 Novo is among those who will probably be exempt
- ·1 t sittenNew comparative data gives the Wegovy pill the upper hand While the market yesterday focused on Eli Lilly's FDA approval of their first obesity pill, Foundayo (orforglipron), Novo Nordisk today presented strong data positioning their oral 25 mg semaglutide (Wegovy in pill form) as market-leading in efficacy. Here are the key points from the fresh analysis being presented at the Obesity Medicine Association (OMA) in San Diego this week: 1. Efficacy gap: +3.2 % in Novo's favor Through an indirect treatment comparison (ITC) study based on the ORION program, the data shows that: * Novo Nordisk's 25 mg oral semaglutide achieved an average weight loss that was 3.2 % higher than Lilly's 36 mg orforglipron. * Although both medications are highly effective, this gap is statistically significant and could be decisive for doctors choosing treatment for their patients. 2. Tolerability and adherence One of the biggest challenges with GLP-1 medications in tablet form is side effects such as nausea. Novo's data indicates that the likelihood of patients discontinuing treatment due to side effects was lower for oral semaglutide than for Lilly's alternative. This is critical for long-term treatment of chronic obesity. 3. Patients prefer Novo's profile Novo also presented figures from a comprehensive patient survey (November 2025): * 84 % of respondents preferred treatment characteristics consistent with Novo's pill. * This includes factors such as dosing flexibility and the established safety profile of the semaglutide molecule. Strategic assessment Lilly's pill (Foundayo) has an advantage in that it does not require fasting before intake, but Novo's response shows that they are betting everything on maximum efficacy. In a market increasingly characterized by competition, the "gold standard" for weight loss will often carry the most weight with specialists. That Novo publishes this just hours after Lilly's approval shows an aggressive and confident market strategy References: • Novo Nordisk Newsroom (Official announcements): Novo Nordisk News & IR Materials – Here you will find the full announcement about the ORION data published April 2, 2026. • Details on competitor's approval (Eli Lilly - Foundayo): PR Newswire: FDA approves Lilly’s Foundayo™ (orforglipron) • Medical coverage of the case: TIME: FDA Approves Eli Lilly’s Obesity Pill, Foundayo • Conference information (OMA 2026): Obesity Medicine Association - Annual Meeting – Complete posters and datasets from the ORION study will be available here during the congress April 8–12.
- ·3 t sittenTrump with tough message: 100 percent tariff Donald Trump is putting massive pressure on the pharmaceutical industry with a new, tough plan. The USA will introduce a 100 percent tariff on patented medicine that is not produced in the USA or is not part of price agreements with the authorities, Reuters writes. The companies get 120 days to comply, otherwise the hammer will fall. They can, however, get off cheaper by moving production to the USA or entering into agreements on lower prices. The measure is intended to push down medicine prices in the USA, where patients today pay significantly more than in other rich countries. The Danish pharmaceutical giant Novo Nordisk has already entered into an agreement with the American administration on lower prices for diabetes and obesity medicine. This happened in november.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt